**Earnings Conference Call Summary - Hematology & Oncology Franchise**

**Key Financial Highlights:**

1. **Revenue Growth:**
   - The Hematology & Oncology franchise reported a solid 10% year-over-year revenue growth for the third quarter.
   - REVLIMID sales increased by 10% year-over-year domestically and saw a 4% growth in ex-U.S. markets, factoring out volatility effects from the previous year.
   - POMALYST/IMNOVID witnessed a substantial 22% year-over-year growth with significant contributions from new geographic regions and increased market share.
   - ABRAXANE sales grew by 8% globally; with domestic growth at 3% and international growth reaching 15%.

2. **Product Performance:**
   - REVLIMID continues to gain market share and duration in newly diagnosed multiple myeloma and post stem cell transplant maintenance settings.
   - POMALYST/IMNOVID performance was robust, particularly strong following the approval of the triplet regimen in relapsed/refractory multiple myeloma.
   - ABRAXANE remains a leading treatment in the pancreatic cancer segment and shows stable demand in metastatic breast cancer and non-small-cell lung cancer.

3. **Strategic Developments:**
   - The franchise has made significant progress in advancing its pipeline with upcoming Phase 3 data readouts in lymphoma, multiple myeloma, and pancreatic cancer.
   - New drug applications and pivotal trial initiations, including marizomib for glioblastoma and various CAR-T therapy programs, are projected to fuel future growth.
   - Notable advancements include the potential transformational asset bb2121 in the relapsed/refractory multiple myeloma space and collaborations with BeiGene and Juno Therapeutics to enhance clinical development strategies.

4. **Regulatory and Market Expansion:**
   - Recent FDA approval of IDHIFA for IDH2-mutant relapsed/refractory AML and successful product launches signal strong regulatory success.
   - International expansion remains potent with REVLIMIDâ€™s reimbursement success in France and other markets for multiple indications.

5. **Future Outlook:**
   - Continued emphasis on enrollment and data readouts from pivotal Phase 3 studies.
   - Expansion plans for the usage of existing drugs in new regimens and combinations.
   - High expectations from the upcoming ASH Congress presentations and updates in the pipeline including next-generation treatments like the CELMoD derivatives.

**Conclusion:**
The Hematology & Oncology franchise at Celgene has demonstrated robust financial and operational growth this quarter, backed by strong sales of key brands and aggressive pipeline development. The firm's strategic initiatives in expanding indications, entering new markets, and advancing new therapeutic modalities position it well for continued success. Future growth will likely be fueled by the progression of late-stage clinical assets and the potential approval and launch of new treatments in critical care areas, reflecting a promising trajectory for sustained growth and market leadership.